By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Blueprint Medicines 



Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-585-2033 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Blueprint Medicines (BPMC) Announces Pricing Of Public Offering Of Shares Of Common Stock 12/8/2016 8:46:43 AM
Blueprint Medicines (BPMC) Announces Proposed Public Offering Of Shares Of Common Stock 12/7/2016 7:03:21 AM
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Phase 1 Clinical Trial Of BLU-285 In Patients With Advanced Systemic Mastocytosis 12/5/2016 6:32:39 AM
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Phase 1 Clinical Trial Of BLU-285 In Patients With Advanced Gastrointestinal Stromal Tumors 12/1/2016 11:08:52 AM
Blueprint Medicines (BPMC) Announces Proof-Of-Concept Data From Global Phase 1 Clinical Trial Of BLU-554 In Patients With Advanced Hepatocellular Carcinoma 11/29/2016 7:37:35 AM
Blueprint Medicines (BPMC) Announces Appointment Of Marion Dorsch, Ph.D. As Chief Scientific Officer And The Transition of Christoph Lengauer, Ph.D., MBA, To A Newly Created Executive Vice President Role 11/15/2016 7:01:05 AM
Blueprint Medicines (BPMC) Reports Third Quarter 2016 Financial Results 11/11/2016 1:17:20 PM
Blueprint Medicines (BPMC) To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016 11/4/2016 6:51:49 AM
Blueprint Medicines (BPMC) Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions For The Treatment Of Fibrolamellar Carcinoma At 10th International Liver Cancer Association (ILCA) Annual Conference 9/9/2016 11:00:23 AM
Blueprint Medicines (BPMC) To Present At Morgan Stanley Global Healthcare Conference 9/7/2016 10:56:20 AM
12345678
//-->